RATIONALE: Interventional clinical trials involving children with septic shock would benefit from an efficient preenrollment stratification strategy. OBJECTIVES: To test the predictive value of interleukin (IL)-8 for 28-day mortality in pediatric septic shock. METHODS: A training data set (n = 40) identified a serum IL-8 of greater than 220 pg/ml as having a 75% sensitivity and specificity for predicting 28-day mortality. This cutoff was then subjected to a series of validation steps. MEASUREMENTS AND MAIN RESULTS: Subjects were drawn from two large, independent pediatric septic shock databases. Prospective application of the IL-8 cutoff to validation data set 1 (n = 139) demonstrated 78% sensitivity and 64% specificity for 28-day mortality. A serum IL-8 level of 220 pg/ml or less, however, had a negative predictive value for 28-day mortality of 95% in validation data set 1, which was subsequently applied to an independently generated data set of children with septic shock (validation set 2, n = 193). A serum IL-8 level of 220 pg/ml or less had a negative predictive value for 28-day mortality of 94% when applied to validation set 2. CONCLUSIONS: A serum IL-8 level of 220 pg/ml or less, obtained within 24 hours of admission, predicts a high likelihood of survival in children with septic shock. We propose that IL-8 can be used to exclude such patients from interventional clinical trials and ultimately derive a study population with a more favorable risk to benefit ratio when subjected to a study agent.
RATIONALE: Interventional clinical trials involving children with septic shock would benefit from an efficient preenrollment stratification strategy. OBJECTIVES: To test the predictive value of interleukin (IL)-8 for 28-day mortality in pediatric septic shock. METHODS: A training data set (n = 40) identified a serum IL-8 of greater than 220 pg/ml as having a 75% sensitivity and specificity for predicting 28-day mortality. This cutoff was then subjected to a series of validation steps. MEASUREMENTS AND MAIN RESULTS: Subjects were drawn from two large, independent pediatric septic shock databases. Prospective application of the IL-8 cutoff to validation data set 1 (n = 139) demonstrated 78% sensitivity and 64% specificity for 28-day mortality. A serum IL-8 level of 220 pg/ml or less, however, had a negative predictive value for 28-day mortality of 95% in validation data set 1, which was subsequently applied to an independently generated data set of children with septic shock (validation set 2, n = 193). A serum IL-8 level of 220 pg/ml or less had a negative predictive value for 28-day mortality of 94% when applied to validation set 2. CONCLUSIONS: A serum IL-8 level of 220 pg/ml or less, obtained within 24 hours of admission, predicts a high likelihood of survival in children with septic shock. We propose that IL-8 can be used to exclude such patients from interventional clinical trials and ultimately derive a study population with a more favorable risk to benefit ratio when subjected to a study agent.
Authors: E B Cook; J L Stahl; L Lowe; R Chen; E Morgan; J Wilson; R Varro; A Chan; F M Graziano; N P Barney Journal: J Immunol Methods Date: 2001-08-01 Impact factor: 2.303
Authors: S Fujishima; J Sasaki; Y Shinozawa; K Takuma; H Kimura; M Suzuki; M Kanazawa; S Hori; N Aikawa Journal: Intensive Care Med Date: 1996-11 Impact factor: 17.440
Authors: Malgorzata A Verboon-Maciolek; Steven F T Thijsen; Marieke A C Hemels; Marjolein Menses; Anton M van Loon; Tannette G Krediet; Leo J Gerards; Andre Fleer; Hieronymus A M Voorbij; Ger T Rijkers Journal: Pediatr Res Date: 2006-03 Impact factor: 3.756
Authors: Thomas P Shanley; Natalie Cvijanovich; Richard Lin; Geoffrey L Allen; Neal J Thomas; Allan Doctor; Meena Kalyanaraman; Nancy M Tofil; Scott Penfil; Marie Monaco; Kelli Odoms; Michael Barnes; Bhuvaneswari Sakthivel; Bruce J Aronow; Hector R Wong Journal: Mol Med Date: 2007 Sep-Oct Impact factor: 6.354
Authors: Thomas Horisberger; Stephan Harbarth; David Nadal; Oskar Baenziger; Joachim E Fischer Journal: Crit Care Date: 2004-10-19 Impact factor: 9.097
Authors: Hector R Wong; Natalie Cvijanovich; Geoffrey L Allen; Richard Lin; Nick Anas; Keith Meyer; Robert J Freishtat; Marie Monaco; Kelli Odoms; Bhuvaneswari Sakthivel; Thomas P Shanley Journal: Crit Care Med Date: 2009-05 Impact factor: 7.598
Authors: Hector R Wong; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Scott L Weiss; Thomas P Shanley; Michael T Bigham; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Jerry J Zimmerman Journal: Am J Respir Crit Care Med Date: 2014-04-15 Impact factor: 21.405
Authors: Erin K Stenson; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie C Fitzgerald; Paul A Checchia; Keith Meyer; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Shekhar S Raj; Shira Gertz; Jocelyn R Grunwell; Hector R Wong Journal: Pediatr Crit Care Med Date: 2018-02 Impact factor: 3.624
Authors: Hector R Wong; Robert J Freishtat; Marie Monaco; Kelli Odoms; Thomas P Shanley Journal: Pediatr Crit Care Med Date: 2010-05 Impact factor: 3.624